BAPTA-AM 是一种可透过细胞膜的钙螯合剂 (Ca2+chelator)。在 HEK 293 细胞中,BAPTA-AM 阻断hERG,hKv1.3和hKv1.5通道,IC50分别为 1.3,1.45 和 1.23 μM。
生物活性 | BAPTA-AM is a well-known membrane permeableCa2+chelator. BAPTA-AM inhibitshERGchannels,hKv1.3andhKv1.5channels in HEK 293 cells withIC50s of 1.3 μM, 1.45 μM and 1.23 μM, respectively[1]. |
IC50& Target | Ca2+chelator[1] IC50: 1.3 μM (hERG channel, in HEK 293 cells), 1.45 μM (hKv1.3, in HEK 293 cells), 1.23 μM (hKv1.5, in HEK 293 cells)[1] |
体外研究 (In Vitro) | BAPTA-AM inhibits neuronal Ca2+-activated K+channel currents, and up-regulates the decreased cardiac sodium current (INa) density by chelating intracellular Ca2+[1]. BAPTA-AM (BAPTA/AM), an intracellular calcium chelator, induces delayed necrosis by lipoxygenase-mediated free radicals in mouse cortical cultures. BAPTA-AM prevents free radical-mediated toxicity promote apoptosis in non-neuronal cells and produce a beneficial effect in neuronal cells by protecting neurons from ischemic damage. In addition, it has been suggested that BAPTA-AM induces a late, but not early, increase of intracellular calcium in I-IL-60 neoplastic cells. Mixed cortical cell cultures (DIV 13-16) exposed to 10 μM BAPTA-AM for 24- or 48-hr show moderate (45-70%) neuronal injury as evaluated by increased LDH release into the bathing medium after 24-48-hr. Exposure of cortical cultures to 3-10 μM BAPTA-AM for 48-hr evoke dose-dependent neuronal damage[2].
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 50 mg/mL(65.39 mM;Need ultrasonic) H2O :< 0.1 mg/mL (ultrasonic)(insoluble) 配制储备液 1 mM | 1.3077 mL | 6.5387 mL | 13.0774 mL | 5 mM | 0.2615 mL | 1.3077 mL | 2.6155 mL | 10 mM | 0.1308 mL | 0.6539 mL | 1.3077 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (3.27 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (3.27 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: 2.5 mg/mL (3.27 mM); Suspended solution; Need ultrasonic
此方案可获得 2.5 mg/mL (3.27 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (3.27 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (3.27 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|